ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

Core Viewpoint - ProSomnus, Inc. is positioned to support patients with Obstructive Sleep Apnea (OSA) following the discontinuation of many OSA devices by Philips Respironics, which has affected approximately 4 million patients [1][2] Group 1: Company Positioning - ProSomnus offers precision intraoral devices that have shown excellent efficacy, adherence, and patient preference in clinical studies, including comparisons with CPAP devices [2] - The company connects sleep physicians with local providers who accept medical insurance and Medicare, ensuring high patient satisfaction [2] - ProSomnus is prepared to facilitate access to healthcare for millions of untreated OSA patients, emphasizing the safety and effectiveness of its devices based on scientific data from numerous studies [2] Group 2: Industry Implications - The exit of Philips Respironics from the U.S. sleep business creates a significant gap in the market, necessitating collaboration between healthcare providers and Dental Sleep Medicine (DSM) specialists to offer alternative treatment options [2][3] - Oral Appliance Therapy (OAT) is highlighted as a highly effective, non-invasive alternative to traditional CPAP therapy, particularly for patients with less severe OSA [2][3] - The discontinuation of CPAP devices is expected to lead to supply chain issues, affecting patient access to care, which ProSomnus aims to address with its precision appliances [2][3] Group 3: Market Context - OSA affects over 1 billion people globally and is associated with serious comorbidities such as heart failure, stroke, and type 2 diabetes [3] - ProSomnus devices are FDA-cleared, patented, and covered by various medical insurance plans, representing over 200 million covered lives [3][4]